Panbela Therapeutics, Inc.: Panbela Announces Adoption of Co

MINNEAPOLIS, Jan. 19, 2023). Previously, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to SBP-101. "We are pleased to receive notice that the European Commission has adopted

Related Keywords

United States , Jenniferk Simpson , Tammy Groene , Committee For Orphan Medicinal Products , Panbela Therapeutics Inc , European Union , European Commission , Nasdaq Stock Market , Drug Administration , Orphan Medicinal Products , Chief Executive Officer , Orphan Medicinal , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports , Panbela , Herapeutics , Nnounces , Adoption , Commission , Implementing , Decision , Rom , Orphan , Resignation , Vospemin , Combination , Gemcitabine , Paclitaxel , Patients , Metastatic , Pancreatic , Ductal , D ,